Crosstalk between interferon and interleukin-1 antiviral signaling in cancer cells: implications for immune evasion and therapeutic resistance

Morten Frier Gjerstorff

doi:10.3389/fimmu.2023.1219870

Crosstalk between interferon and interleukin-1 antiviral signaling in cancer cells: implications for immune evasion and therapeutic resistance

Morten Frier Gjerstorff^*

^*Kontaktforfatter

Publikation: Bidrag til tidsskrift › Kommentar/debat › Forskning › peer review

22 Downloads (Pure)

Originalsprog	Engelsk
Artikelnummer	1219870
Tidsskrift	Frontiers in Immunology
Vol/bind	14
Antal sider	4
ISSN	1664-3224
DOI	https://doi.org/10.3389/fimmu.2023.1219870
Status	Udgivet - 8. jun. 2023

Bibliografisk note

Funding Information:
The study was supported by the Region of Southern Denmark, Pink Tribute, Einar Willumsens foundation, Carl and Ellen Hertzs foundation, Phycician Sofus Carl Emil Friis and spouse’s foundation, Neye foundation, Agnes and Poul Friis foundation, Emil C. Hertz and spouse’s foundation, Frimodt-Heineke foundation, Olga Doris Friis foundation, Dagmar Marshalls foundation, the Danish Cancer Society, the Novo Nordisk foundation, and the Danish Research Council for Independent Research. The funders were not involved in the study design, collection, analysis,interpretation of data, the writing of this article or the decision to submit it for publication.

Dokumenter og links

10.3389/fimmu.2023.1219870Licens: CC BY

Open Access VersionForlagets udgivne version, 869 KBLicens: CC BY

Citationsformater

@article{bc0df7ef0a364c3d83cd78de6ab538cd,

title = "Crosstalk between interferon and interleukin-1 antiviral signaling in cancer cells: implications for immune evasion and therapeutic resistance",

keywords = "interferon, interleukin 1, myeloid-derived suppressor cells (MDSC), therapeutic resistance, tumor immunity, Interleukin-1, Immune Evasion, Interferons, Antiviral Agents/pharmacology, Neoplasms/drug therapy, Drug Resistance, Neoplasm",

author = "Gjerstorff, {Morten Frier}",

note = "Funding Information: The study was supported by the Region of Southern Denmark, Pink Tribute, Einar Willumsens foundation, Carl and Ellen Hertzs foundation, Phycician Sofus Carl Emil Friis and spouse{\textquoteright}s foundation, Neye foundation, Agnes and Poul Friis foundation, Emil C. Hertz and spouse{\textquoteright}s foundation, Frimodt-Heineke foundation, Olga Doris Friis foundation, Dagmar Marshalls foundation, the Danish Cancer Society, the Novo Nordisk foundation, and the Danish Research Council for Independent Research. The funders were not involved in the study design, collection, analysis,interpretation of data, the writing of this article or the decision to submit it for publication. ",

year = "2023",

month = jun,

day = "8",

doi = "10.3389/fimmu.2023.1219870",

language = "English",

volume = "14",

journal = "Frontiers in Immunology",

issn = "1664-3224",

publisher = "Frontiers",

}

TY - JOUR

T1 - Crosstalk between interferon and interleukin-1 antiviral signaling in cancer cells

T2 - implications for immune evasion and therapeutic resistance

AU - Gjerstorff, Morten Frier

N1 - Funding Information: The study was supported by the Region of Southern Denmark, Pink Tribute, Einar Willumsens foundation, Carl and Ellen Hertzs foundation, Phycician Sofus Carl Emil Friis and spouse’s foundation, Neye foundation, Agnes and Poul Friis foundation, Emil C. Hertz and spouse’s foundation, Frimodt-Heineke foundation, Olga Doris Friis foundation, Dagmar Marshalls foundation, the Danish Cancer Society, the Novo Nordisk foundation, and the Danish Research Council for Independent Research. The funders were not involved in the study design, collection, analysis,interpretation of data, the writing of this article or the decision to submit it for publication.

PY - 2023/6/8

Y1 - 2023/6/8

KW - interferon

KW - interleukin 1

KW - myeloid-derived suppressor cells (MDSC)

KW - therapeutic resistance

KW - tumor immunity

KW - Interleukin-1

KW - Immune Evasion

KW - Interferons

KW - Antiviral Agents/pharmacology

KW - Neoplasms/drug therapy

KW - Drug Resistance, Neoplasm

U2 - 10.3389/fimmu.2023.1219870

DO - 10.3389/fimmu.2023.1219870

M3 - Comment/debate

C2 - 37359511

AN - SCOPUS:85163344963

SN - 1664-3224

VL - 14

JO - Frontiers in Immunology

JF - Frontiers in Immunology

M1 - 1219870

ER -